Hydroflux (Furosemide Sodium)

Hydroflux is indicated for the management of several conditions characterized by excess fluid accumulation. The drug is administered by injection and is commonly used when rapid diuresis is required.

• Edema associated with congestive heart failure, helping to reduce peripheral and pulmonary fluid buildup.
• Acute pulmonary edema where swift removal of excess lung water is clinically important.
• Cirrhotic ascites, providing diuretic support to manage abdominal fluid accumulation in liver disease.
• Renal disease with fluid overload, such as nephrotic syndrome or acute kidney injury, to aid in volume control.
• Hypertension that is refractory to first‑line therapy, where a loop diuretic may be added to lower blood pressure.

• Furosemide sodium acts on the thick ascending limb of the loop of Henle by inhibiting the Na⁺/K⁺/2Cl⁻ cotransporter. This blockade reduces reabsorption of sodium, chloride, and potassium, creating an osmotic gradient that prevents water from being reabsorbed. The resulting increase in urinary output leads to rapid elimination of excess extracellular fluid and a decrease in blood volume, contributing to its diuretic effect.

Adverse reactions to Hydroflux may vary in frequency and severity.

Common

• Electrolyte disturbances such as low potassium (hypokalemia) or low sodium (hyponatremia).
• Dehydration and increased thirst.
• Dizziness or light‑headedness, especially when standing.
• Hearing changes, including tinnitus, when high doses are given rapidly.
• Increased urination (polyuria) leading to nocturia.
• Mild gastrointestinal upset such as nausea or abdominal cramping.

Serious

• Severe electrolyte imbalance leading to cardiac arrhythmias.
• Acute kidney injury or worsening renal function.
• Significant drops in blood pressure (hypotension) causing syncope.
• Ototoxicity with permanent hearing loss at very high intravenous rates.

When prescribing Hydroflux, clinicians should evaluate patient history and monitor several clinical parameters to minimize risk.

• Assess renal function before initiation and periodically during therapy.
• Monitor serum electrolytes, especially potassium, sodium, and chloride, throughout treatment.
• Use caution in patients with hearing impairment or those receiving high intravenous doses.
• Evaluate volume status to avoid excessive dehydration or hypotension.
• Consider dose adjustment in elderly patients or those with hepatic impairment.
• Avoid use in patients with known hypersensitivity to furosemide or sulfonamide derivatives.
• Review concomitant use of other diuretics to prevent additive electrolyte loss.

Hydroflux can interact with other medicines, altering its diuretic effect or increasing the risk of adverse events.

Avoid

• Concurrent use with other potent loop diuretics, which may cause excessive fluid and electrolyte loss.
• Combination with aminoglycoside antibiotics, which can increase the risk of ototoxicity.
• Co‑administration with digitalis glycosides may increase the risk of digitalis toxicity due to electrolyte shifts.

Use with caution

• NSAIDs, because they may reduce the diuretic response.
• ACE inhibitors or ARBs, which together can enhance hypotensive effects and affect renal function.
• Antihypertensive agents, requiring blood pressure monitoring.
• Lithium therapy, as furosemide can raise lithium levels.
• Corticosteroids can potentiate potassium loss, so electrolyte monitoring is advised.